Results 21 to 30 of about 3,203 (180)

Perfil antiinflamatorio del paricalcitol en el receptor de trasplante renal

Nefrología, 2017
Antecedentes y objetivos: El paricalcitol, un activador selectivo del receptor de la vitamina D, se utiliza en el tratamiento del hiperparatiroidismo secundario en el receptor de trasplante renal. Estudios tanto clínicos como experimentales realizados en
Javier Donate-Correa, Fernando Henríquez-Palop, Ernesto Martín-Núñez, Carolina Hernández-Carballo, Carla Ferri, Nayra Pérez-Delgado, Mercedes Muros-de-Fuentes, Carmen Mora-Fernández, Juan F. Navarro-González   +8 more
doaj   +2 more sources

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection

Clinical Interventions in Aging, 2013
Darko Duplancic,1 Marijan Cesarik,2 Nikola Kolja Poljak,3 Maja Radman,4 Vedran Kovacic,5 Josipa Radic,5 Veljko Rogosic61Department of Cardiology, School of Medicine in Split, University Hospital Split, Split, Croatia; 2Department for Neurology, County ...
Duplancic D, Cesarik M, Poljak NK, Radman M, Kovacic V, Radic J, Rogosic V   +6 more
doaj   +1 more source

A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.

PLoS ONE, 2020
Paricalcitol, a new vitamin D receptor activator (VDRA), is reported to be more effective than other VDRAs in reducing calcium and phosphorus levels in patients undergoing hemodialysis.
Xinghua Geng, Ermin Shi, Shiwei Wang, Yuzhi Song   +3 more
doaj   +1 more source

Paricalcitol improved cardiac hypertrophy and fibrosis through upregulation of fibroblast growth factor-23 and downregulation of transforming growth factor-beta in a rat model of isoproterenol-induced cardiomyopathy

Chinese Journal of Physiology, 2023
Acute cardiomyopathy is a significant global health concern and one of the leading causes of death in developed countries. Prior studies have shown an association between acute cardiomyopathy and low vitamin D levels.
Chieh-Jen Wu, Yu-He Li, Hsin-Hung Chen
doaj   +1 more source

Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E₂ receptor EP4

Kidney Research and Clinical Practice, 2017
Background: Vitamin D is considered to exert a protective effect on various renal diseases but its underlying molecular mechanism remains poorly understood.
Yu Ah Hong, Keum Jin Yang, So Young Jung, Yoon Kyung Chang, Cheol Whee Park, Chul Woo Yang, Suk Young Kim, Hyeon Seok Hwang   +7 more
doaj   +1 more source

Cinacalcet, paricalcitol, or both? [PDF]

Nephrology Dialysis Transplantation, 2007
n ...
M. Cozzolino, A. Galassi, D. Brancaccio
openaire   +4 more sources

Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Dysfunctional endothelium may contribute to the development of cardiovascular complications in chronic kidney disease (CKD). Supplementation with active vitamin D has been proposed to have vasoprotective potential in CKD, not only by direct ...
Marc Vila Cuenca, Evelina Ferrantelli, Elisa Meinster, Stephan M. Pouw, Igor Kovačević, Renee X. de Menezes, Hans W. Niessen, Robert H.J. Beelen, Peter L. Hordijk, Marc G. Vervloet   +9 more
doaj   +1 more source

The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model

Journal of Diabetes Research, 2020
Background. Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes and is the leading cause of end-stage renal disease (ESRD) and replacement therapy worldwide.
Nakhoul Nakhoul, Tina Thawko, Evgeny Farber, Inbal Dahan, Hagar Tadmor, Rola Nakhoul, Anaam Hanut, Ghasan Salameh, Ibrahim Shagrawy, Farid Nakhoul   +9 more
doaj   +1 more source

Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats

Kidney & Blood Pressure Research, 2014
Background/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats.
Zehra Eren, Mehmet Yalçin Günal, Elif Arı Bakir, Jale Coban, Berrak Çağlayan, Nur Ekimci, Sinem Ethemoglu, Ozgur Albayrak, Tuba Akdeniz, Gülderen Yanikkaya Demirel, Ertuğrul Kiliç, Gülçin Kantarci   +11 more
doaj   +1 more source

Comparison of Paricalcitol (I.V) and Alfacalcidol (I.V) in Treatment of Secondary Hyperparathyroidism (SHPT) in Hemodialysis Patients

Journal of Rawalpindi Medical College, 2020
Objective of study: To Compare the efficacy of Alfacalcidol (I.V) and Paricalcitol (I.V) for the treatment of secondary hyperparathyroidism  (SHPT)  in hemodialysis patients.
Mansoor Abbas Qaisar, Zain ul Abideen, Fateh Sher Chattah, Muhammad Nadeem, Zahid Hafeez   +4 more
doaj   +1 more source